Docket No.: PF-0509 USN

IN THE CLAIMS

Please cancel claims 1-20 without prejudice or disclaimer.

Please add the following new claims 21-34.

For the Examiner's convenience, all pending claims are listed below. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

- 21. (New) An isolated polypeptide selected from the group consisting of:
- a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-65,
- a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-65,
 - a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-65, and
- b) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-65.
- 22. (New) An isolated polynucleotide encoding a polypeptide of claim 21.
- 23. (New) A recombinant polynucleotide comprising a promoter sequence operably linked to the polynucleotide of claim 22.
 - 24. (New) A cell transformed with the recombinant polynucleotide of claim 23.

2

25. (New) A transgenic organism comprising the recombinant polynucleotide of claim 23

a) b)

- 26. (New) A method of producing a polypeptide of claim 21, the method comprising:
- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 21, and
- b) recovering the polypeptide so expressed.
- 27. (New) An isolated antibody which specifically binds to a polypeptide of claim 21.
- 28. (New) An isolated polynucleotide selected from the group consisting of:
- a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:66-69 and SEQ ID NO:71-130,
- a polynucleotide comprising a polynucleotide sequence at least 90% identical to a
 polynucleotide sequence selected from the group consisting of SEQ ID NO:66-69 and
 SEQ ID NO:71-130,
- c) a polynucleotide complementary to a polynucleotide of a),
- d) a polynucleotide complementary to a polynucleotide of b) and
- e) an RNA equivalent of a)-d).
- 29. (New) An isolated polynucleotide selected from the group consisting of:
- a) a polynucleotide comprising the polynucleotide sequence of SEQ ID NO:70,
- b) a polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence of SEQ ID NO:70,
- c) a polynucleotide complementary to the polynucleotide of a),
- d) a polynucleotide complementary to a polynucleotide of b) and
- e) an RNA equivalent of a) -d).

108921 3 09/674,743

Docket No.: PF-0509 USN

30. (New) A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 29, the method comprising:

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
- 31. (New) A method of claim 30, wherein the probe comprises at least 60 contiguous nucleotides.
- 32. (New) A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 29, the method comprising:
 - a) amplifying said target polynucleotide using polymerase chain reaction amplification, and
 - b) detecting the presence or absence of said amplified target polynucleotide and optionally, if present, the amount thereof.
- 33. (New) A composition comprising the polypeptide of claim 21 and a pharmaceutically acceptable excipient.
- 34. (New) A method for treating a disease or condition associated with decreased expression of functional HTRM, comprising administering to a patient in need of such treatment the composition of claim 33.

108921 4 09/674,743